Compare Amphastar Pharmaceuticals Inc (AMPH) vs Global Payments Inc (GPN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Global Payments (GPN) trades at $76.04, up 2.23% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company maintains solid operating cash flow of $2.66B for 2025 and a gross profit margin of 67.34%, though net income margin turned negative at -7.97% for 2026. Recent developments include AI-powered POS launches and expansion of restaurant partnerships, driving positive analyst sentiment with a consensus price target of $81.56.

GPN presents a mixed outlook: upside exists from earnings momentum and strategic initiatives like the Worldpay integration, but risks include margin pressure, rising debt-to-asset ratio of 41.57%, and intense fintech competition. The stock's current valuation at a P/E of 27.96 appears reasonable relative to growth prospects, yet investors must weigh execution risks against potential rewards in a competitive payments landscape.